Lupus Nephritis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 102 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Lupus Nephritis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Lupus Nephritis - Pipeline Review, H2 2014', provides an overview of the Lupus Nephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lupus Nephritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lupus Nephritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Lupus Nephritis Overview 8
Therapeutics Development 9
Pipeline Products for Lupus Nephritis - Overview 9
Pipeline Products for Lupus Nephritis - Comparative Analysis 10
Lupus Nephritis - Therapeutics under Development by Companies 11
Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes 13
Lupus Nephritis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Lupus Nephritis - Products under Development by Companies 17
Lupus Nephritis - Products under Investigation by Universities/Institutes 18
Lupus Nephritis - Companies Involved in Therapeutics Development 19
Bristol-Myers Squibb Company 19
Johnson & Johnson 20
F. Hoffmann-La Roche Ltd. 21
Biogen Idec Inc. 22
GlaxoSmithKline plc 23
Millennium Pharmaceuticals, Inc. 24
Teva Pharmaceutical Industries Limited 25
Invion Limited 26
Anthera Pharmaceuticals� Inc. 27
Kadmon Corporation, LLC 28
Azano Pharmaceuticals Inc. 29
Lupus Nephritis - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
belimumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
abatacept - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
laquinimod sodium - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BIIB-023 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
KD-025 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
voclosporin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
sirukumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ixazomib citrate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
blisibimod - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
INV-103 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AZ-175 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ZY-11 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Anti-ImmunoglobulinE - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
dexamethasone conjugate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
RO-5461111 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Y-175L - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Lupus Nephritis - Recent Pipeline Updates 71
Lupus Nephritis - Dormant Projects 94
Lupus Nephritis - Discontinued Products 95
Lupus Nephritis - Product Development Milestones 96
Featured News & Press Releases 96
Jun 26, 2014: Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis 96
May 19, 2014: XTL Biopharmaceuticals Further Strengthens Team for Phase II Lupus Trial with Two Additional Experts 96
May 05, 2014: Kadmon Corporation Presents Results of KD025 Preclinical and Clinical Studies at AAI Annual Meeting 97
Oct 15, 2013: Kadmon Announces Development Plans for Selective ROCK 2 Inhibitor, KD025, in Psoriasis, Lupus Nephritis and NASH 98
Jun 12, 2013: Teva And Active Biotech Report Positive Results From Phase IIa Study Of Laquinimod In Active Lupus Nephritis 98
Jun 03, 2010: CellCept Reached Positive Results In Phase III Trial In Lupus Nephritis 99
Jan 29, 2010: Bindarit A MCP-1/CCL2 Production Inhibitor 100
Jun 27, 2007: Preliminary Results For Phase III Study Evaluating CellCept In Lupus Nephritis. 100
Jan 26, 2007: Approval of Prograf for Lupus Nephritis in Japan 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102

List of Tables
Number of Products under Development for Lupus Nephritis, H2 2014 9
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H2 2014 19
Lupus Nephritis - Pipeline by Johnson & Johnson, H2 2014 20
Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 21
Lupus Nephritis - Pipeline by Biogen Idec Inc., H2 2014 22
Lupus Nephritis - Pipeline by GlaxoSmithKline plc, H2 2014 23
Lupus Nephritis - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 24
Lupus Nephritis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 25
Lupus Nephritis - Pipeline by Invion Limited, H2 2014 26
Lupus Nephritis - Pipeline by Anthera Pharmaceuticals� Inc., H2 2014 27
Lupus Nephritis - Pipeline by Kadmon Corporation, LLC, H2 2014 28
Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Lupus Nephritis Therapeutics - Recent Pipeline Updates, H2 2014 71
Lupus Nephritis - Dormant Projects, H2 2014 94
Lupus Nephritis - Discontinued Products, H2 2014 95